(Q44470007)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

Athanasios Dimopoulos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jesús San Miguel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

ESMO Guidelines Working Group

7 March 2020

8

object named as

ESMO Guidelines Working Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

P Moreau

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H Ludwig

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H Schouten

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Mohty

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Dreyling

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

16 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

24 Suppl 6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

vi133-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT297

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23956208%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference